Cue Biopharma to Present Corporate Update at 2019 BIO CEO & Investor Conference

World News: . []

CAMBRIDGE, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- , Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will be presenting an update at the BIO CEO & Investor Conference on Tuesday, February 12, 2019, at 10:00 am ET (Hudson/Empire Room), at the New York Marriott Marquis Hotel, NY.  Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer, will provide an overview of the Company's Immuno-STAT™ platform and development strategy as well as pre-clinical data updates on key programs and anticipated milestones. A live and archived version of the webcast will be available at . The presentation will also be archived for 30 days on the Investors section of the Company's website at .

The lead program from the CUE-100 framework, CUE-101, contains IL-2 and a pMHC composed of HLA-A*02:01 complexed with a dominant peptide derived from the human papilloma virus E7 protein (HPV-E7). The drug is a fusion protein biologic designed to target and activate antigen-specific T cells to attack HPV-driven cancers.

The simultaneous engagement of co-stimulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT Biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered in vivo, they are fundamentally different from other T cell therapeutic approaches such as Adoptive Cell Therapy (ACT), which require the patients’ T cells to be extracted, then stimulated and expanded outside the body (ex vivo) and reinfused in an activated state.

We believe our selective biologics allow us to target antigen-specific T cell populations in a variety of indications using a peptide – MHC complex for delivering T cell modulating effectors, such as IL-2. Once a biologic has been optimized, our approach offers the potential for readily exchanging peptides to target different T cell populations and indications using previously-validated drug frameworks developed from the Immuno-STAT(Selective Targeting and Alteration of T cells) platform. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost-efficiently than current industry standards.

Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit .

Investor Contact: John Woolford Westwicke Partners 443-213-0506

Media Contact: Mike Beyer Sam Brown Inc. 312-961-2502 

More news and information about Cue Biopharma, Inc.

Published By:

Globe Newswire: 21:30 GMT Monday 11th February 2019

Published: .

Search for other references to "biopharma" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us